RE: BSspiral: ONC has 19 months of cash on handONC has 19 months of cash on hand...reported loss decreases over time, as it recently has quarter over quarter, the operating time increases proportionately to the reduction in the overall burn rate.
give me a break - typical misleading and unchallenged BS posted here with only two possible explanations - you are stupid and don't know any better or more likely you are purposely attempting to mislead people.
from the release
The Company continued to incur R&D expenses as it studied the efficacy and safety of REOLYSIN® in its clinical trial program and completed its animal toxicology study examining systemic delivery of REOLYSIN®.
the glio trials were shut down for the last 6 months which means those R&D costs were lower than they will be now that the trial has resumed - and the financial results don't include costs for systemic trials which according to BT at least, are going to commence "soon".
for 2002, they burned an average $550K in cash per month - or $6.6M per year (and clinical trials were only conducted for 7 out of those 12 months). the 3rd quarter was the only qtr last year where both trials were in full progress without interruption and the R&D costs for that quarter amounted to $1.6M.
that is much more realistic burn rate to use to estimate the cash they have left and it translates to 12 months before considering systemic trial costs and phase II glio costs in $US.
addition of the ph II systemic trial should conservatively add 50% of the exisitng 2 trials R&D costs, then add 33% of the systemic and phase II glio costs to the total to account for them being conducted in the US and you have an unconservative burn rate of about $700K per month - meaning they have 9 months before they run completely out of cash.
anything less than 12 is extremely risky - if they go under 6, they are playing with fire but it will be the shareholders (not option holders) who will be burned.
or perhaps you are going to suggest that most of their R&D relates to developing the manufacturing process for a naturally occuring virus easily reproduced in lab conditions than the trials needed to actually get it approved to treat cancer?